Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today announced a slate of training and educational activities for physicians at the upcoming LEAD (Latest Endovascular Atherectomy Devices) Course and AMP (Amputation Prevention) Symposium in Chicago. CSI is a sponsor of the LEAD Course for Fellows on August 9, where physicians have the opportunity to receive in-depth reviews of the types of devices they will use in their practices. CSI will also host training for physicians at a pre-conference symposium on the afternoon of August 9, to learn more about best-practice techniques in amputation prevention. This symposium features leading physicians, including Drs. Jihad Mustapha, Raymond Dattilo, Utpal Desai, George Pliagas and Sumeet Sachdev. On August 10, CSI is offering a hands-on cadaver training course for physicians who have a desire to learn antegrade and retrograde tibial and pedal ultrasound guided access. This new access treatment option provides physicians with more options in treating difficult below-the-knee (BTK) cases where smaller vessels are often more heavily calcified. The event will take place from 5:30-8:30 p.m. Participants will be taught how to identify six pivotal points of access (anterior, posterior, peroneal, dorsalis pedal, plantar and digital arteries). Dr. Jihad Mustapha, who will lead the course, said, “Gaining effective access in these areas of the body can be challenging, particularly pedal access, but with advances in technology I will assist participants in hands-on instruction allowing them access in less than 30 seconds. A full BTK procedure may now be completed in less than 30 minutes based on greater access and effective treatment options.” Participation in this special program is limited and physicians should contact the CSI Medical Education Department by email at email@example.com. David L. Martin, CSI president and chief executive officer, said, “We remain committed to investing in medical education and training for physicians. This training course and hands-on experience with our Orbital Atherectomy System allows physicians to learn how to use our technology efficiently and effectively to defeat complex calcium issues in peripheral arteries as a primary treatment therapy, giving them an alternative to life-altering amputation in difficult cases.”
During the last day of the symposium on August 11, CSI is co-sponsoring Terumo Interventional Systems’ Simple Tools and Techniques for Complex BTK Cases symposium. The presentation begins at 12:15 in the Crystal room, and features Sven Braeunlich, MD, and Jihad Mustapha, MD.To find out more about CSI’s Orbital Atherectomy System technology or any events underway at the AMP 2012 Symposium, visitors can visit CSI at booth 16 in the exhibit hall at the Palmer House Hilton Hotel on August 10-11. About Peripheral Arterial DiseasePAD is a life-threatening condition where a fatty material called plaque builds up on the inside walls of the blood vessels that carry blood from the heart to legs and arms. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow to the legs. The risk of PAD increases if a person has one or several of the following: high blood pressure, abnormal cholesterol levels, diabetes, or personal history of heart disease, heart attack or stroke. PAD affects an estimated 8-12 million people in the United States. The disease prevalence increases with age and 12-20 percent of Americans age 65 and older suffer from PAD symptoms. As the U.S. population ages, the prevalence range could reach 16 million in those age 65 and older and 19 million overall by 2050. About Cardiovascular Systems, Inc.Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Diamondback Orbital Atherectomy System treats calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, more than 70,000 PAD procedures have been performed using CSI’s technology in leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States. Cardiovascular Systems, Inc. For more information, visit the company’s website at www.csi360.com.